BSR_07_0008_A3_S73
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.370
- ESTROGEN_RESPONSE_EARLY+0.360
- OXIDATIVE_PHOSPHORYLATION+0.330
- ADIPOGENESIS+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190
- FATTY_ACID_METABOLISM+0.180
- APOPTOSIS+0.160
- GLYCOLYSIS+0.140
- APICAL_SURFACE+0.130
- DNA_REPAIR+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- ANGIOGENESIS-0.310
- IL2_STAT5_SIGNALING-0.270
- ALLOGRAFT_REJECTION-0.220
- IL6_JAK_STAT3_SIGNALING-0.210
- KRAS_SIGNALING_UP-0.210
- ANDROGEN_RESPONSE-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- E2F_TARGETS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313112 | — | B | 0.757 |
| 2 | AUR-AFUP-TTM1-A-1-1-R-A743-41 | — | B | 0.746 |
| 3 | SRR1313117 | — | B | 0.725 |
| 4 | SRR1326179 | GTEX | — | 0.714 |
| 5 | 9f9dec84-0c2c-4f85-8024-b8fb1de1eb81 | — | — | 0.710 |
| 6 | 486430aa-f745-4353-9e03-6226ac8d9993 | — | — | 0.704 |
| 7 | MNG1112 | — | — | 0.703 |
| 8 | TCGA-D8-A1JI-01A-11R-A13Q-07 | — | B | 0.692 |
| 9 | TCGA-E2-A106-01A-11R-A10J-07 | — | B | 0.690 |
| 10 | 20040108.LumA | — | B | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.370 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |